Detectable Prostate Specific Antigen Between 60 and 120 Days Following Radical Prostatectomy for Prostate Cancer: Natural History and Prognostic Significance

Journal of Urology

Volumn 176, Issue 2, 2006, Pages 559-563

  Sengupta, Shomik ^a   Christensen, Carl M ^a   Zincke, Horst ^a   Slezak, Jeffrey M ^a   Leibovich, Bradley C ^a   Bergstralh, Eric J ^a   Myers, Robert P ^a   Blute, Michael L ^a  

^a MAYO CLINIC   (United States)

Author keywords

prognosis; prostate specific antigen; prostatectomy; prostatic neoplasms; survival

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; DEATH; FOLLOW UP; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; RECURRENT DISEASE; SEMINAL VESICLE; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 33745228430     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.03.086     Document Type: Article

References (10)

1. Cheng W.S., Bergstralh E.J., Frydenberg M., and Zincke H. Prostate-specific antigen levels after radical prostatectomy and immediate adjuvant hormonal treatment for stage D1 prostate cancer are predictive of early disease outcome. Eur Urol 25 (1994) 189
2. Amling C.L., Bergstralh E.J., Blute M.L., Slezak J.M., and Zincke H. Defining prostate specific antigen progression after radical prostatectomy. what is the most appropriate cut point?. J Urol 165 (2001) 1146
3. Roberts S.G., Blute M.L., Bergstralh E.J., Slezak J.M., and Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 76 (2001) 576
4. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591
5. Moul J.W. Variables in predicting survival based on treating "PSA-only" relapse. Urol Oncol 21 (2003) 292
6. Ravery V. The significance of recurrent PSA after radical prostatectomy. benign versus malignant sources. Semin Urol Oncol 17 (1999) 127
7. Rogers C.G., Khan M.A., Craig Miller M., Veltri R.W., and Partin A.W. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy. Cancer 101 (2004) 2549
8. Blute M.L., Bergstralh E.J., Iocca A., Scherer B., and Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 165 (2001) 119
9. Nativ O., Winkler H.Z., Raz Y., Therneau T.M., Farrow G.M., Myers R.P., et al. Stage C prostatic adenocarcinoma. flow cytometric nuclear DNA ploidy analysis. Mayo Clin Proc 64 (1989) 911
10. Ward J.F., Blute M.L., Slezak J., Bergstralh E.J., and Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170 (2003) 1872